Showing results (61-70 of 317) with videos related to
Sort By:
Pageof 32
International Journal of Cancer|February 15, 1990
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinationsR Mortarini, F Belli, G Parmiani, et al.International Journal of Cancer|December 15, 1990
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicityM Sensi, M Bergomi, F Formelli, et al.Melanoma Research|July 1, 1992
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?G Parmiani, A Anichini, G Carbone, et al.Journal of Immunogenetics|April 1, 1977
Multiple foreign non-H-2 determinants on the surface of a chemically-induced murine sarcomaG Invernizzi, G Carbone, A Meschini, et al.Neurosurgery|June 1, 1994
Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case reportA Silvani, A Salmaggi, G Parmiani, et al.British Journal of Cancer|June 1, 1971
Immunodepression during urethane and N-nitrosomethylurea leukaemogenesis in miceG Parmiani, M I Colnaghi, G Della PortaHuman Immunology|June 1, 1990
Multiple VLA antigens on a subset of melanoma clonesA Anichini, R Mortarini, E Berti, et al.British Journal of Cancer|August 1, 1986
In vivo characterization of a doxorubicin resistant B16 melanoma cell lineF Formelli, C Rossi, R Supino, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1989
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interactionA Anichini, A Mazzocchi, G Fossati, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases modelM Rodolfo, C Salvi, C Bassi, et al.Pageof 32